On March 14, 2023 Seagen Inc. (Nasdaq: SGEN) reported the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in Orlando from April 14-19, 2023 (Press release, Seagen, MAR 14, 2023, View Source [SID1234628685]). The broad range of data being presented at this year’s meeting includes research from Seagen’s approved medicines, as well as data from early-stage clinical, preclinical, and discovery research programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Seagen’s robust presence at AACR (Free AACR Whitepaper) this year, highlighting progress across our diverse pipeline, underscores our commitment to improving and extending the lives of people living with cancer," said Roger Dansey, M.D., President of Research and Development and Chief Medical Officer at Seagen. "As a pioneer in antibody-drug conjugates, we strive to optimize and expand the potential of our core technology, while also progressing innovative, targeted cancer approaches."
Highlights include an interim analysis from the innovaTV 207 Phase 2 study of tisotumab vedotin (TV) given every 2 weeks in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have progressed after prior platinum combination, immunotherapy, and targeted therapy, if eligible. TV, which is being developed in partnership with Genmab, is a tissue factor (TF)-directed antibody-drug conjugate (ADC). The innovaTV 207 study is currently ongoing and evaluating alternative dosing regimens of TV across multiple advanced solid tumors.
Other notable clinical data include initial results from a Phase 1 dose-escalation study of SEA-TGT monotherapy in patients with advanced malignancies. SEA-TGT is a novel investigational nonfucosylated human IgG1 antibody directed against TIGIT, an inhibitory immune checkpoint receptor that has emerged as a clinically relevant immuno-oncology target. SEA-TGT continues to be evaluated both as monotherapy and in combination with an anti-PD1 agent.
Seagen will also present new preclinical findings on the antitumor activity of disitamab vedotin, an ADC that targets cancers expressing HER2, as a monotherapy and in combination with tucatinib in breast and gastric cancer models, and on SGN-B6A, a wholly-owned, first-in-class vedotin ADC that targets integrin beta-6, which is highly expressed in a range of solid tumors.
Seagen and Sanofi will also unveil the first preclinical data from a novel topoisomerase I inhibitor ADC targeting CEACAM5, showing potent antitumor activity in patient-derived colorectal cancer models. These are the first data disclosed from the companies’ 2022 collaboration to develop and commercialize multiple novel ADCs.
Additional preclinical data disclosures are planned, highlighting vedotin programs and novel ADC and tumor targeting technologies, including payloads with immune stimulatory properties.
Details of Seagen Presentations at AACR (Free AACR Whitepaper) Annual Meeting 2023
Abstract Title
Abstract #
Presentation Time
Lead Author
ADCETRIS (brentuximab vedotin)
CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors
3253
Poster Presentation
Clinical Research Excluding Trials / Combination Immunotherapies 1
Mon., April 17
1:30 – 5:00 p.m. ET
B. Grogan
Exposure-response and age subgroup analyses to support body-weight (BW) dosing of brentuximab vedotin (BV) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults (aged 2-21 years [y]): A randomized Children’s Oncology Group phase 3 trial (AHOD1331)
6737
Poster Presentation
Clinical Research Excluding Trials / Preclinical Therapies and Clinical Observations in Pediatric Oncology
Wed., April 19
9:00 a.m. – 12:30 p.m. ET
Z. Zhang
PADCEV (enfortumab vedotin)
Enfortumab vedotin, a Nectin-4-directed antibody-drug conjugate, demonstrates compelling antitumor activity in non-muscle invasive bladder cancer models and accurately predicts minimal systemic exposure when administered by intravesical instillation in patients
LB246
Poster Presentation
Late-Breaking Research: Experimental and Molecular Therapeutics 2
Tues., April 18
1:30 – 5:00 p.m. ET
D. Olson
TIDVAK (tisotumab vedotin)
Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207
CT164
Poster Presentation
Phase II Clinical Trials 1
Mon., April 17
1:30 – 5:00 p.m. ET
B. Cirauqui
TUKYSA (tucatinib)
Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial-in-progress)
CT065
Poster Presentation
Phase II and Phase III Clinical Trials in Progress
Mon., April 17
9:00 a.m. – 12:30 p.m. ET
E. Hamilton
Tucatinib does not alter oxaliplatin PK or associated renal function: An OCT2/MATE transport inhibition study
5060
Poster Presentation
Experimental and Molecular Therapeutics – Theranostics and Radionuclides / Pharmacologic Approaches
Tues., April 18
1:30 – 5:00 p.m. ET
A. Topletz-Erickson
Disitamab Vedotin
Disitamab vedotin, an investigational HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical cancer models
560
Poster Presentation
Experimental and Molecular Therapeutics / Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1
Sun., April 16
1:30 – 5:00 p.m. ET
K. Willis
Early-Stage Programs
SGN-BB228, a CD228-directed costimulatory antibody anticalin bispecific provides potent and conditional 4-1BB costimulation to T cells in vivo and in an in vitro model of T-cell exhaustion
5676
Poster Presentation
Clinical Research Excluding Trials / Therapeutic Antibodies, Including Engineered Antibodies
Tues., April 18
1:30 – 5:00 p.m. ET
B. Updegraff
SGN-B6A induces immunogenic cell death as an additional mechanism of action
1522
Poster Presentation
Experimental and Molecular Therapeutics / Antibody-Drug Conjugates
Mon., April 17
9:00 a.m. – 12:30 p.m. ET
V. Trang
Generation of an antibody-drug conjugate-optimized TLR7/8 agonist payload
1542
Poster Presentation
Experimental and Molecular Therapeutics / Antibody-Drug Conjugates
Mon., April 17
9:00 a.m. – 12:30 p.m. ET
K.P. Wang
Phase 1 dose-escalation study of SEA-TGT monotherapy in patients with advanced malignancies
CT265
Poster Presentation
Phase I Clinical Trials 2
Tues., April 18
1:30 – 5:00 p.m. ET
E. Garralda Cabanas
Using a clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD)
5668
Poster Presentation
Clinical Research Excluding Trials / Therapeutic Antibodies, Including Engineered Antibodies
Tues., April 18
1:30 – 5:00 p.m. ET
G. Patilea-Vrana
A preclinical model of acquired anti-PD-1 resistance is responsive to SEA-TGT, an effector-function enhanced anti-TIGIT monoclonal antibody
6361
Poster Presentation
Immunology / Immune Checkpoints
Wed., April 19
9:00 a.m. – 12:30 p.m. ET
D. Gruber
A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent antitumor activity in colorectal cancer models
4890
Poster Presentation
Experimental and Molecular Therapeutics / Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment
Tues., April 18
1:30 – 5:00 p.m. ET
Y. Baudat
Discovery Research
Oxidized anthracycline payloads induce antitumor immunogenic cell death and show linker-dependent tolerability when delivered as ADCs
2013
Poster Presentation
Chemistry / Drug Delivery
Mon., April 17
9:00 a.m. – 12:30 p.m. ET
J. Hamilton
Reversible chemical modification of antibodies: A complementary approach to tuning FcγR binding that maintains antitumor activity while mitigating peripheral immune activation
2656
Poster Presentation
Experimental and Molecular Therapeutics / Antibody Technologies
Mon., April 17
9:00 a.m. – 12:30 p.m. ET
P. Moquist
MMAE drives immunomodulatory changes in a preclinical xenograft model that are distinct from other clinical-stage ADC payloads
4892
Poster Presentation
Experimental and Molecular Therapeutics / Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment
Tues., April 18
1:30 – 5:00 p.m. ET
M. Ulrich